JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

15.13 -0.66

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

14.71

Max

15.63

Galvenie mērījumi

By Trading Economics

Ienākumi

3.9M

4.5M

Pārdošana

5.9M

24M

EPS

0.35

Dividenžu ienesīgums

0.48

Peļņas marža

18.669

Darbinieki

212

EBITDA

4.9M

7.2M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+4.51% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.24%

Nākamie ieņēmumi

2026. g. 13. jūl.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

51M

302M

Iepriekšējā atvēršanas cena

15.79

Iepriekšējā slēgšanas cena

15.13

Ziņu noskaņojums

By Acuity

6%

94%

7 / 348 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 23. apr. 00:00 UTC

Galvenie ziņu notikumi

Australian Flash PMI Bounce in April Conceals Deeper Worries

2026. g. 22. apr. 23:33 UTC

Peļņas

SK Hynix Posts Record Quarterly Results Amid AI Boom

2026. g. 22. apr. 22:40 UTC

Peļņas

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

2026. g. 22. apr. 22:10 UTC

Iegādes, apvienošanās, pārņemšana

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

2026. g. 22. apr. 21:11 UTC

Peļņas

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

2026. g. 22. apr. 21:01 UTC

Peļņas

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

2026. g. 22. apr. 23:46 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 22. apr. 23:46 UTC

Tirgus saruna

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

2026. g. 22. apr. 23:34 UTC

Tirgus saruna
Galvenie ziņu notikumi

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

2026. g. 22. apr. 23:16 UTC

Peļņas

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

2026. g. 22. apr. 23:15 UTC

Peļņas

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

2026. g. 22. apr. 22:54 UTC

Peļņas

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

2026. g. 22. apr. 22:54 UTC

Peļņas

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

2026. g. 22. apr. 22:52 UTC

Peļņas

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

2026. g. 22. apr. 22:51 UTC

Peļņas

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

2026. g. 22. apr. 22:31 UTC

Peļņas

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

2026. g. 22. apr. 22:31 UTC

Peļņas

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

2026. g. 22. apr. 22:30 UTC

Peļņas

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

2026. g. 22. apr. 22:30 UTC

Peļņas

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

2026. g. 22. apr. 22:29 UTC

Peļņas

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

2026. g. 22. apr. 22:28 UTC

Peļņas

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

2026. g. 22. apr. 22:28 UTC

Peļņas

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

2026. g. 22. apr. 22:27 UTC

Peļņas

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

2026. g. 22. apr. 22:06 UTC

Tirgus saruna
Peļņas

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

2026. g. 22. apr. 21:55 UTC

Iegādes, apvienošanās, pārņemšana

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

2026. g. 22. apr. 21:47 UTC

Peļņas

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

2026. g. 22. apr. 21:37 UTC

Peļņas

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

2026. g. 22. apr. 21:34 UTC

Peļņas

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

2026. g. 22. apr. 21:29 UTC

Peļņas

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

2026. g. 22. apr. 21:20 UTC

Tirgus saruna
Peļņas

Tesla Expands Manufacturing to Chips -- Market Talk

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

4.51% augšup

Prognoze 12 mēnešiem

Vidējais 16 USD  4.51%

Augstākais 16 USD

Zemākais 16 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

2

Pirkt

1

Turēt

0

Pārdot

Noskaņojums

By Acuity

7 / 348 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat